Columbia University faculty present research on a previously unknown type of immune cell in kidney tumors that can predict which patients are likely to have cancer recur after surgery.

Patients with Bacillus Calmette-Guerin (BCG)-unresponsive bladder cancer remain a challenging patient population to treat. Radical cystectomy continues as the oncologic gold standard treatment in patients at high risk of recurrence after BCG failure in non-muscle-invasive bladder cancer.

Robotic-assisted radical cystectomy has assumed its rightful place in the skill set of urologic oncologists. The application of robotics to perform radical cystectomy has been steadily increasing since its introduction nearly two decades ago.

Today, there are more options for the treatment of bladder cancer than ever before. Urologic oncologists in the Department of Urology at NewYork-Presbyterian/Columbia are established experts in both robotic and laparoscopic techniques for the treatment of urologic tumors, specifically bladder, kidney, prostate, and testicular cancer.

In kidney transplantation, laparoscopic donor nephrectomy is now the standard of care for living donors, a technique not widely available until the late 1990s.

Peter J. Stahl, MD, gravitated to the subspecialty of reproductive and sexual medicine for a simple reason. This field provides an opportunity to make a big difference in someone’s life.

For more than three decades, the Departments of Urology at NewYork-Presbyterian have contributed greatly to the growing body of knowledge about men’s sexual and reproductive health.

Weill Cornell Medicine has been awarded a five-year, $11.3 million Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute to improve the detection, diagnosis, and treatment of prostate cancer.